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Clinical Outcomes and Cataract Formation Rates in Eyes
10Years After Posterior Phakic Lens Implantation forMyopia
Ivo Guber, MD; Victoria Mouvet, MD; Ciara Bergin, PhD; Sylvie Perritaz, BScOptom;
Philippe Othenin-Girard, MD; François Majo, MD, PhD
IMPORTANCE Intraocular collamer lenses (ICLs) are posterior chamber phakic lenses that
provide a refractive surgery option for those with highmyopia or astigmatism. The short-term
andmidterm results indicate good refraction stability, efficacy, and safety. Cataract has been
suggested to be an important long-term complication of ICL implantation.
OBJECTIVE To report the rates of cataract development and refractive outcomes 10 years
after ICL implantation.
DESIGN, SETTING, AND PARTICIPANTS The study included 133 eyes of 78 patients undergoing
consecutive V4model ICL implantations, which took place from January 1, 1998, through
December 31, 2004, at Jules-Gonin Eye Hospital, Lausanne, Switzerland. Data analysis was
performed from January 1, 2014, to May 31, 2014. The lenses implanted were as follows: 53
V4model ICLs of −15.5 D or greater, 73 V4model ICLs of less than −15.5 diopter (D), and 7 V4
model toric ICLs for myopia.
MAIN OUTCOMES ANDMEASURES Rate of cataract surgery, lens opacity, ocular hypertension,
refractive safety, predictability, and stability.
RESULTS A total of 133 eyes of 78 patients (34men and 44women, with a mean [SD] age of
38.8 [9.2] years at enrollment) met the inclusion criteria. The rate of lens opacity
development was 40.9% (95% CI, 32.7%-48.8%) and 54.8% (95% CI, 44.7%-63.0%) at 5
and 10 years, respectively. Phacoemulsification was performed in 5 eyes (4.9%; 95% CI,
1.0%-8.7%) and 18 eyes (18.3%; 95% CI, 10.1%-25.8%) at 5 and 10 years after ICL
implantation, respectively. The vault height (distance between the posterior ICL surface and
anterior lens surface) measured amean (SD) of 426 (344) μm immediately postoperatively,
decreasing to 213 (169) μm at 10 years. A smaller vault height was associated with the
development of lens opacity and phacoemulsification (P = .005 and .008, respectively). The
intraocular pressure was 15 mmHg postoperatively, and there was no significant increase in
intraocular pressure observed until the 10-year follow-up (16mmHg, P = .02). At 10 years, 12
eyes (12.9%; 95% CI, 5.6%-19.6%) had developed ocular hypertension that required topical
medication. At 10 years, the mean (SD) safety index was 1.25 (0.57), with a manifest spherical
equivalent of −0.5 D at 1-year postoperatively vs −0.7 D at 10 years postoperatively in eyes
aimed at emmetropia.
CONCLUSIONS AND RELEVANCE This retrospective single center study indicates that ICL
implantation provides good long-term safety and stability of refraction in patients with high
myopia compared with similar short-term studies. However, the rates of cataract formation
and ocular hypertension at 10 years have important clinical implications, and as such this
information should be part of the available patient information before ICL implantation.
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F or patients with high ametropia or thin cornea, refrac-tive surgery options are limited; in this case, implanta-tion of artificial intraocular phakic lenses is often apre-
ferredoption.1-5 In younger patients, implantationof artificial
intraocular phakic lenses allows the retention of the crystal-
line lens and accommodation, without altering the corneal
biostructure.4 Three types of phakic intraocular lenses exist:
anterior chamber angle–fixated lens, anterior chamber iris–
fixated lens, and posterior chamber sulcus–fixated lens.
Alió et al6 reported high rates of cataract (64%), endothe-
lial cell loss (24%), and pupil ovalization (10%) with angle-
supported phakic intraocular lenses. The detrimental effects
ontheendotheliumwith this lens typeultimately result inpen-
etrating endothelial keratoplasty. Anterior chamber iris–
fixated lenses have had greater success in terms of astigma-
tism correction, where the iris claw prevents rotation. A
meta-analysis7 comparing this model type with the posterior
implantable collamer lens (ICL; Staar Surgical AG) revealed
similar efficacy andbetter predictability butmore cataract de-
velopment with the posterior ICL, particularly in the V2 and
V3models;however, iris claw lenseshavebeenassociatedwith
continuous endothelial cell loss.
The V4model ICL was introduced in 1998 and is the sole
sulcus-supported model approved by the US Food and Drug
Administration. The short-term andmidterm outcomes after
V4model ICL implantation inmyopic eyeshave revealedgood
safety, efficacy (of attainingdesiredmanifest refraction), pre-
dictability (of lens strength required postoperatively), and
refraction stability over time.2,8-19 However, to our knowl-
edge, there are only 2 reports20,21 on outcomes after 5 years.
Schmidinger et al20 reported outcomes on cataract and vault
height (distance between the posterior ICL surface and ante-
rior lens surface) at a mean of 96 months after ICL implanta-
tion; in this report,20 17% of cases required phacoemulsifica-
tion during follow-up, and an additional 28% presented with
lens opacity. Igarashi et al21 reported that, at 8 years after ICL
implantation, 5% of cases required phacoemulsification and
an additional 20% presented with lens opacity. These re-
ports, among others,20-25 indicate that cataract is an impor-
tant long-termcomplicationof ICL implantation, especially in
eyes with limited vaulting.20,23,26
The aims of this study are to report the rate of complica-
tions, particularlywith cataract (lens opacity andphacoemul-
sification), and investigate the association with vaulting. In
addition, we aimed to report the safety, efficacy, predictabil-
ity, and stability at set postoperative time points (1, 2, 5, and
10 years) in a large cohort of patients with myopia who have
undergone ICL implantation (V4model) and to compare these
results with those available in the literature.
Methods
This retrospective studywas approved by the Cantonal Com-
mittee for Ethics and Human Research, Vaud, Lausanne, and
adhered to the tenets of the Declaration of Helsinki.27 All (n =
133)V4model ICL implantationsperformedat Jules-GoninEye
Hospital in Lausanne, Switzerland, from January 1, 1998,
throughDecember31, 2004,were reviewed.Data analysiswas
performed fromJanuary 1, 2014, toMay31, 2014. Patients had
stable refraction for more than 1 year, an anterior chamber
depth greater than 2.8mmmeasured from the endothelium,
highendothelial cell density (ECD) (>2000cells/mm2), nopre-
vious intraocular surgery or history of ocular hypertension or
uveitis or preexisting ocular disease (eg, glaucoma), and no
history of diabetes mellitus. The surgical technique has been
previously described.1
A large proportion of eyes (n = 73) were operated on be-
fore the introduction of the V4 model toric ICLs and suffi-
ciently strong ICLpowers; therefore, the inserted lenswasnot
aimed at achieving emmetropia in a proportion of these eyes.
A subgroup analysis was performed on those eyes ( n = 60)
intended for emmetropia.
Preoperative examination, including slitlamp examina-
tionwith intraocularpressure (IOP) assessment, correcteddis-
tance visual acuity (CDVA), uncorrected distance visual
acuity (UDVA),manifest refraction, biometry (IOLMaster, Carl
Zeiss Meditec Inc), and ECD assessment with the noncontact
specularmicroscope,wasperformedwith2devices (from1998
until 2007, EM-3000, Tomey; and from 2007 on, Seaeagle,
Rhine-Tec GmbH).
Lens Calculation
The calculation of the power of the lenses wasmade by Staar
Surgical AG based on the measurements of manifest refrac-
tion and refraction after cycloplegy, keratometry (ARK-700A
[NidekCoLtd] or IOLMaster), pachymetry, andanterior cham-
ber depth (Haag-Streit depth-measuring system 7200018
[Haag-Streit] or IOLMaster). The length of the implanted ICL
wasdeterminedbyStaar Surgical AG, dependingon thewhite
to white distance, measuredwith the use of callipers on digi-
tal images taken with a Scheimpflug camera (Nidek Co Ltd).
Postoperative Follow-up
All available data from postoperative visits performed at 6
months and 1, 2, 5, and 10 years postoperatively were col-
lated. Follow-upexaminations included a full slitlampexami-
nation with IOP, CDVA, UDVA, and manifest refraction. Dur-
ing follow-up, thecrystalline lensandthe ICLwereperiodically
photographedwith the Scheimpflug camera,withdilatedpu-
pils, allowing full visualizationof the crystalline lens.Thecen-
tral vault height was measured on photographs taken by the
Key Points
Question:What are the long-term outcomes of patients with
myopia and posterior phakic intraocular collamer lens (ICL) in situ?
Findings: In a retrospective review of consecutive patients with an
ICL, the observed rate of phacoemulsification increased from
4.9% at 5 years to 18.3% at 10 years after ICL implantation and
13% of eyes developed ocular hypertension that required topical
therapy at 10 years.
Meaning: The elevated risk of ocular hypertension and lens
opacity after ICL implantation dictates that regular follow up of
these patients is mandatory.
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Scheimpflugcameraorondigitalphotographs taken in the180°
axis using the EAS-1000 software program, version 1.23E, for
Windows (Nidek EAS-1000, Nidek Co Ltd).
Statistical Analysis
At the study center, visual acuitywas recorded indecimal for-
mat; therefore, the visual acuity was converted to logMAR to
calculatemeanvaluesandsubsequently reconverted intodeci-
mal format.All available visit datawere collectedandgrouped
with respect to the closest time point. If more than 1 visit was
available within a given grouping, then the visit data closest
to the given timepointwereused in the analysis. Baseline and
follow-up data at each time point for the cohort were com-
pared using analysis of variance (ANOVA). The patient iden-
tification number and eye were entered into themodel to ac-
count for intereye correlations. For lens opacity survival
analysis, the time fromICL implantationuntil lensopacitywas
first noted was calculated; if no lens opacity was noted, the
data were censored at the last available visit. For phacoemul-
sificationsurvival analysis, the time fromICL implantationun-
til phacoemulsification was calculated; if no phacoemulsifi-
cation was performed for those eyes with less than 10 years
of follow-up data available, the datawere censored at the last
available visit.
Results
A total of 133 eyes of 78 patients (34men and 44women)met
the inclusion criteria; the baseline characteristics are pro-
vided in Table 1. Seventy-five eyes (56.4%) from 45 patients
were examined at the 10-year follow-up appointment, an ad-
ditional 15 eyes (11.3%) had undergone phacoemulsification,
and 43 eyes (32.3%) were lost to follow-up at 10 years. In the
eTable in the Supplement, eyes with and without 10 years of
follow-up were compared. Of age, IOP, ECD, and spherical
equivalent,only spherical equivalent revealedasignificantdif-
ference in baseline characteristics. The implanted ICL mod-
els were 53 V4 model ICLs of −15.5 diopter (D) or greater, 73
V4model ICLs of less than −15.5 D, and 7 V4model toric ICLs
for myopia. Sixty eyes were aimed at emmetropia; these are
referred to as the emmetropic group.
Safety Outcome (All Eyes)
Decimal CDVAs are provided inTable 2. Themean (SD) safety
indexes (mean postoperative CDVA divided by mean preop-
erative CDVA) were 1.42 (0.51), 1.46 (0.61), 1.43 (0.52), 1.42
(0.57), and 1.25 (0.57) at 6months and 1, 2, 5, and 10years, re-
spectively. Ten years postoperatively, 1 eye had lost 3 lines, 3
eyes had lost 2 lines, 7 had eyes lost 1 line, and the rest of the
eyes were equal or better than preoperative measurements.
These findings are summarized for all time points in Figure 1.
Themean logMARCDVAswere0.04,0.01,0.01,0.04and0.05
at 6 months and 1, 2, 5 and 10 years, respectively.
Efficacy Outcome (Emmetropic GroupOnly)
Decimal UDVAs are provided in Table 2 for all time points. In
the emmetropic subgroup analysis, themean (SD) efficacy in-
dexes (mean postoperative UDVA divided bymean preopera-
tiveCDVA)were1.03 (0.3),0.95 (0.4), 1.00 (0.3),0.92 (0.4), and
0.76 (0.4) at 6 months and 1, 2, 5, and 10 years, respectively.
Predictability (Emmetropic GroupOnly)
In the emmetropic subgroup analysis, at 6months and 1, 2, 5,
and 10 years, 31 (55.4%) of 56, 21 (51.2%) of 41, 17 (37.0%) of
46, 12 (27.9%)of43,and17 (48.6%)of35eyes, respectivelywere
within±0.5Dof the intendedcorrection, and46 (82.1%)of 56,
34 (73.9%) of 46, 31 (75.6%) of 41, 25 (58.1%) of 43, and 23
(65.7%) of 35 eyes, respectively, were within ±1.0 D of the in-
tended correction.
Stability (All Eyes)
The spherical equivalentwas stable throughout follow-up.At
6monthsand1, 2, 5, and10years after surgery, themeanmani-
fest spherical equivalent was −0.4, −0.5, −0.7, −0.8, and −0.7
D, respectively, in the group aimed at achieving emmetropia,
and the manifest spherical equivalent was −0.3, −0.5, −0.8,
−0.9, and−1.1, respectively, in thewholegroup.Althoughthere
weresignificantchanges inspherical equivalentduring the first
year (P = .007, ANOVA), there was no change in the spherical
equivalent observed with longer follow-up.
Complications
Eighteen eyes were observed to have an early complication
(<1 year) after ICL implantation, 10 eyes had transient el-
evated IOP postoperatively, and 1 eye had excessive anterior
chamber inflammation (suspected toxic anterior segment syn-
drome). Four eyeshadperipheral contact between the ICLand
lens; 1eyedevelopedmyopicchoroidalneovascularization.One
patient had excessive glare, but this resolved after surgical re-
duction of the iridectomy. In the late postoperative phase (>1
year), 20 complications were observed in 19 eyes. Two eyes
of 2 patients developedmyopic choroidal neovascularization
1.6 and 11.2 years after ICL implantation. One eye of 1 patient
developedcentral atrophyof thepigmentepithelium2.8years
after surgery, and 1 eye of 1 patient developed a retinal hole
Table 1. Baseline Characteristics
Characteristic Mean (SD) Median (IQR)
Age, y 38.8 (9.2) 39.1 (31.5 to 45.8)
Distance visual acuity
Uncorrected <.05 <0.05 (<0.05 to 0.1)
Corrected 0.76 (0.24) 0.8 (0.6 to 1.0)
Manifest refraction, D
Sphere 12 (2.9) −12 (−13.8 to −9.5)
Cylinder 0.24 (1.6) −0.5 (−1.25 to 0.8)
Spherical equivalent 11.4 (2.9) −11.25 (−13.2 to −9.1)
ACD, mm 3.58 (0.31) 3.57 (3.34 to 3.80)
Pachymetry, μm 525 (34) 512 (500 to 552)
IOP, mm Hg 15.0 (2.3) 15 (14 to 16)
Corneal diameter, mm 12.0 (0.4) 12 (11.75 to 12.25)
ICL optical power 16.4 (2.9) 16.5 (14.0 to 18.5)
Abbreviations: ACD, anterior chamber depth; D, diopter; ICL, implantable
collamer lens; IOP, intraocular pressure; IQR, interquartile range.
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5.6 years after surgery. There were 16 cases of ocular hyper-
tension controlled with IOP-lowering treatment, developing
amean of 7.3 years (range, 1.4-12 years) after implantation; at
10 years, this corresponds to a rate of 13% (95% CI, 6%-20%).
The survival curve and risk table summarizing these occur-
rence rates at each year are given in eFigure 1 in the Supple-
ment. In these eyes, excessive vault heights were not ob-
served (403 μmon amean of 190-740 μm), but pigmentation
was observed in the iridocorneal angle. The IOP at each time
point is provided inTable 2. Comparing thepostoperative IOP
and thepreoperativemeasures, only IOPs at 10yearshada sig-
nificant increase from baseline (P = .02, ANOVA).
ECD Estimates
The median ECD estimates are provided in Table 2. Changes
in ECD between 6months and 1, 2, and 5 years of 25, 100, and
75 cells/mm2, respectively, were observed, but these changes
werenot statistically significant (paired t test,P = .49, .14, and
Figure 1. Safety Profile at Each Time Point
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Table 2. PostoperativeMeasures at Each of the Postoperative Time Points
Measure
Median (IQR)
Baseline 6 mo 1 y 2 y 5 y 10 y
No. of eyes 133 133 100 104 106 75
Distance visual acuity
Uncorrected <.05 0.8
(0.5 to 1.0)
0.7
(0.5 to 1.0)
0.8
(0.5 to 1.0)
0.7
(0.45 to 1.0)
0.6
(0.3 to 1.0)
Corrected 0.8
(0.6 to 1.0)
1.0
(0.8 to 1.2)
1.0
(0.8 to 1.25)
1.0
(0.8 to 1.25)
1.0
(0.8 to 1.2)
1.0
(0.8 to 1.2)
Manifest refraction for
distance vision, D
Sphere −12.00
(−13.8 to −9.5)
0.00
(−0.25 to 0.50)
0.00
(−0.75 to 0.50)
−0.25
(−0.75 to 0.25)
−0.25
(−1.00 to 0.25)
−0.25
(−1.00 to 0.25)
Cylinder −0.5
(−1.25 to 0.8)
−1.00
(−1.50 to −0.25)
−1.00
(−1.50 to −0.50)
−1.00
(−1.50 to −0.50)
−1.00
(−1.50 to −0.50)
−0.75
(−1.25 to −0.50)
Spherical equivalent −11.25
(−13.2 to −9.1)
−0.38
(−1.00 to 0.00)
−0.50
(−1.30 to −0.25)
−0.63
(−1.66 to −0.13)
−0.75
(−1.65 to −0.13)
−0.63
(−1.63 to −0.13)
IOP, mm Hg 15
(14 to 16)
14
(13 to 16)
14.5
(13 to 16)
14
(13 to 16)
15
(13 to 16.75)
16
(14 to 18)
ECD, cells/mm2 2300 2275 2300 2242 2200 2393
Emmetropic aimed group
No. of eyes 58 56 41 46 43 35
Distance visual acuity
Uncorrected <0.05 0.9
(0.6 to 1.2)
0.8
(0.5 to 1.0)
0.8
(0.6 to 1.0)
0.8
(0.5 to 1.0)
0.8
(0.3 to 1.0)
Corrected 0.8
(0.8 to 1.0)
1.0
(0.8 to 1.3)
1.0
(0.9 to 1.3)
1.0
(0.9 to 1.3)
1.0
(0.9 to 1.3)
1.0
(0.8 to 1.2)
Spherical equivalent −10.5
(−12.5 to −8.7)
−0.3
(−0.0 to −0.9)
−0.4
(−0.3 to 0.8)
−0.6
(−0.1 to 1.0)
−0.8
(0.0 to −1.3)
−0.4
(0.1 to −1.3)
Abbreviations: D, diopter; ECD, endothelial cell density; IOP, intraocular pressure; IQR, interquartile range.
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.23, respectively). There was an increase of 114 cells/mm2 in
the ECD observed at 10 years, although this was an anomaly,
the probable cause of which is discussed later in this article.
Vaulting, Lens Opacity, and Phacoemulsification (All Eyes)
Vaulting was a mean (SD) of 426 (344) μm at 2 years postop-
eratively. This height decreased significantly to 213 (169) μm
at 10 years (P = .01, ANOVA; eFigure 2 in the Supplement). In
those eyes that required phacoemulsification during follow-
up, amean (SD) reduction in vaulting from307 (237) μm to82
(111) μm before phacoemulsification and ICL extraction oc-
curred. In those eyes with lens opacity observed at the slit-
lamp examination, themean (SD) vaulting was 378 (314) μm,
decreasing to 184 (131) μm at 10 years postoperatively. In the
clear lens group, mean (SD) vaulting was 548 (366) μm after
implantation, decreasing to amean (SD) of 229 (177) μm at 10
years postoperatively.
The rate of lens opacity developmentwas 40.9% (95%CI,
32.7%-48.8%) and 54.8% (95% CI, 44.7%-63.0%) at 5 and 10
years, respectively. Phacoemulsification was performed in 6
eyes (4.9%; 95% CI, 1.0%-8.7%) and 18 eyes (18.3%; 95% CI,
10.1%-25.8%) at 5 and 10years after ICL implantation.Figure2
shows the Kaplan-Meier curves of development of lens opac-
ity and cataract surgery over time, with the corresponding
at-risk table given below each. One eye of 1 patient devel-
oped cataract within the first postoperative year. In this
case, the ICL fit had been unsatisfactory and required a cor-
rective surgery; however, during correction there was cap-
sular touch, which resulted in early postoperative cataract
and phacoemulsification. No other intraoperative complica-
tions were observed. After the correlation between eyes had
been accounted for (ANOVA), the relationship between
vaulting and lens opacity (P = .008) and phacoemulsifica-
tion (P = .005) was significant.
Discussion
This study reports the outcomes and complications 10 years
after ICL implantation.A significant proportionof eyes devel-
oped lensopacity, resulting in approximately one-fifthof eyes
undergoingcataract and ICLextractionduring the first 10years
after ICL implantation. The rates of lens opacity and phaco-
emulsification increasedwith time. This trend coincideswith
trends reported in the literature on lens opacification: 3% of
eyes at 1 year,11 4% to 11% at 2 years,2,10,13,14 7% to 13% at 5
years,25,26 20%at 8 years,21 and 28%at 10 years.20 Thehigher
rate of lens opacity reported in this studymaybeowing to the
wider viewunder full dilationanddetectionofperipheral lens
opacity (eFigure 3 in the Supplement). The rates of phaco-
emulsification aremore similar to those previously reported:
2% to 4% at 2 years,2,10 2% at 5 years,25 5% at 8 years,21 and
17% at 10 years.20 Study results indicate that cataract forma-
tion is a frequent complication of ICL implantation, continu-
ing to develop up to 10 years after ICL implantation.
This isa retrospectivestudy,withassociated limitationwith
respect to potential sources of bias; for example, this cohort
of consecutive cases dates from 1998 and, as such, includes
some highly myopic and astigmatic eyes for which suffi-
ciently powered or toric ICLs were not available, limiting the
possible correction.We tried to control for these confounders
by selecting the emmetropically aimed eyes. However, dur-
ing the past 15 years, lens power calculations have improved,
and it is acceptable that our study reports a lower efficacy and
predictability comparedwithpublications that report theout-
comesofmore recentlyperformedoperations (withshorter fol-
low-up). Of importance, good stability of refraction and high
safety rates were observed during the long-term follow-up;
however, this limitation remains a possible source of bias. In
Figure 2. Kaplan-Meier Curves for the Rate of Lens Opacity and the Rate of Cataract Extraction Over Time
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addition, a significant proportion of eyes that received ICL
implants were lost to follow-up at 10 years (an approximately
5% dropout per year), and, as such, this is a potential source
of bias with respect to the estimation of cataract or hyperten-
sion provided. Comparison of the baseline characteristics of
those with and without 10 years of follow-up does not in-
dicate bias. However, in eyes without 10 years of follow-up,
more had received an ICL with an alternative geometry
implanted (higher myopia >15.5 D; Isabel Argeles, PhD, Staar
SurgicalAG,oral communication,April2015), andagreaterpro-
portionof these eyeshadundergonephacoemulsificationand
thereforewerenot available for the 10-year follow-up.Data are
insufficient to examine this in detail; however, the change in
ICL geometry required for very high-powered lenses is a po-
tential source of bias.
As previously reported, eyes that developed lens opacity
or requiredcataractextractionhad lowerbaselinevaultheights
thaneyes thatmaintaineda clear lens.23 This findingwas later
confirmed by Schmidinger et al.20 A reduction in vault height
with timewasobserved in thestudyeyes,with thevaultheight
decreasing by26.8μmper year. Likewise, Schmidinger et al20
reported a reduction in vault height of 28 μm per year. Fur-
thermore, a reduction in vault height over timewas observed
(subjectively) by Igarashi et al.21 In eyes thatmaintained clear
lens after ICL implantation, Lackner et al16 reported a vault of
355 μm. Schmidinger et al20 reported a mean vault height of
greater than 300μmat 10 years. Considering the reduction in
vault height over time, to maintain an adequate vault height
in the long term (>10 years), the immediate vault height after
surgery should be greater than 550 μm.
The long-term safety of the ICL procedure reveals safety
indexes greater than 1 throughout follow-up (Table 3). On the
basis of a sample size of 133 eyes, we can be confident that
complications will not occur more than 2.3% of the time.28
Table 3. Literature Review of Refractive Outcomes After ICL Implantation of Previously Published Articles at the Available Time Points
Study
Preoperative Postoperative Refractive Outcome Indexes
BCVA UCVA SE BCVA UCVA SE Safety Efficacy
1-y Results
Jiménez-Alfaro et al,13 2001 0.2 2.0 −14.1 0.1 0.3 −1.6 1.4 0.8
Sanders et al,11 2007 … … −9.4 … … … … …
Schallhorn et al,12 2007 0.0 … −8.0 −0.2 … 0.3 1.3 …
Kamiya et al,10 2009 … … −10.0 … … 0.0 … …
Kamiya et al,10 2009 −0.2 1.5 −9.8 −0.2 0.0 0.0 1.1 0.7
Kamiya et al,9 2010 −0.1 1.5 −10.4 −0.2 −0.1 −0.1 1.1 1.0
Igarashi et al,21 2014 −0.1 1.5 −10.9 −0.2 −0.1 −0.2 1.2 0.9
2-y Results
Arne and Lesueur,2 2000 0.2 2.0 −13.9 0.1 0.4 −1.2 1.2 0.7
Jiménez-Alfaro et al,13 2001 0.2 2.0 −14.1 0.1 0.3 −1.6 1.4 0.8
Chung et al,14 2009 0.1 1.3 −14.0 0.0 0.2 … 1.3 0.8
Kamiya et al,10 2009 −0.2 1.5 9.8 −0.2 −0.1 … 1.1 0.9
3-y Results
Lackner et al,16 2004 0.4 1.3 −16.5 0.2 0.4 … 1.4 0.9
Alfonso et al,15 2010 … … −10.1 … … … … …
4-y Results
Dejaco-Ruhswurm et al,17 2002 … … −16.5 … … … … …
Edelhauser et al,18 2004 … … −10.1 … … … … …
Kamiya et al,10 2009 −0.2 1.5 9.8 −0.2 0.0 … 1.1 0.8
Gomez-Bastar et al,192014 0.2 1.7 −11.6 0.1 0.2 −0.5 1.2 1.0
Igarashi et al,21 2014 −0.1 1.5 −10.9 −0.2 −0.1 −0.3 1.2 0.8
5-y Results
Sanders,25 2008 … … … … … … … …
Lindland et al,26 2010 0.1 2.0 −8.9 0.0 0.2 … 1.3 0.7
Alfonso et al,31 2011 0.1 1.3 −11.2 0.1 0.2 −0.9 1.1 0.9
6-y Results
Kamiya et al,34 2014 … … −10.6 … … … … …
8-y Results
Igarashi et al,21 2014 −0.1 1.5 −10.9 −0.2 0.0 −0.4 1.1 0.8
10-y Results
Schmidinger et al,20 2010 … … −15.7 … … … … …
Abbreviations: BCVA, best-corrected visual acuity; ellipses indicate data not available; ICL, intraocular collamer lenses; SE, spherical equivalence;
UCVA, uncorrected visual acuity.
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Efficacyappears to reduce slightlyover time; for example, Iga-
rashi et al20 reported an efficacy of 0.94 at 1 year, decreasing
to0.83 at 8 years. In our cohort, a similar trendwas observed,
with a mild increase in myopia over time. This increased
myopia may in part be owing to the development of nuclear
cataract or myopia progression.21
In short-termtomidtermfollow-up,ECD lossof 7%to 12%
was observed.10,14,16-18,21 This reductionwas observed imme-
diatelyafter surgery (1month)andmaintainedduring thepost-
operative follow-up and is similar to the effect of the surgical
trauma associated with cataract surgery on ECD.29,30 How-
ever, the ECD loss after cataract surgery stabilizes as early as
6weekspostoperatively.30This stabilizationcoincideswith the
results of ICL implantationobserved inprevious reports.10,14,21
Toourknowledge, after the first year,nosignificant loss inECD
has been observed. In this cohort, an increase in ECD esti-
mates was observed 10 years after surgery, which we believe
to be related to a change in device that occurred during fol-
low-upat our institution, but this outcomewould at least sug-
gest that a large loss in ECD is not present.
There were 10 cases of transient hypertension in the
immediate postoperative phase that resolved during year 1,
likely owing to remnants of viscoelastic devices and steroid
responders. No cases of acute glaucoma owing to angle block
were observed in this cohort. In alternative reports9,10,14,21,31
with shorter follow-up, the incidence of chronic glaucoma
ranged from 0% to 5%. No cases of chronic glaucoma were
observed in this cohort. Themean IOP remains stable through-
out follow-up.10,14,21 With the longer follow-up reported in
this study, a significant proportion of study eyes with pig-
mentation in the iridocorneal angle and ocular hypertension
requiring IOP-lowering medication was observed. To our
knowledge, to date, cases of ocular hypertension requiring
treatment have not been discussed, making comparison
impossible.21
Nonsurgical refractive correction in patients with high
myopia remains the first treatment option. In cases of con-
tact lens intolerance or poor visual quality, refractive surgery,
suchas ICL implantation,mayprovidea suitable solution.The
amountof correctionwithphakic intraocular lenses isnot lim-
ited by corneal thickness, and thebiostructure is preserved.32
Iris-fixated phakic intraocular lenses and posterior ICLs are
preferable to clear lens extraction owing to premature loss of
accommodation and increased probability of retinal detach-
ment in this high-risk group.33 Because the mean age was 38
years at implantation and 83% of cases retained their natural
lens at 10 years postoperatively, most cases will have devel-
oped presbyopia before phacoemulsification is required.
Conclusions
This studyconfirms that ICL implantationprovidesgood long-
termsafetyandstabilityof refraction inpatientswithhighmyo-
pia. There is a larger than expected rate of lens opacity and
phacoemulsification,whichcontinuesto increaseupto10years
after surgery.The ratesof ocularhypertensionaregreater than
previously reported. These outcomes have important clinical
implications, and, as such, this information should be part of
the available patient information before ICL implantation.
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Invited Commentary
Long-term Clinical Outcomes and Cataract Formation Rates
After Posterior Phakic Lens Implantation forMyopia
Stephen D. McLeod, MD
Phakic intraocular lenses (PILs) can provide optically superb
correction of relatively highdegrees of ametropia that liewell
beyond the recommended range for keratorefractive proce-
dures, such as laser in situ keratomileusis and photorefrac-
tive keratectomy. Although
hundreds of thousands have
been implanted, thepredomi-
nant concern surrounding
thesedevices remains thatof long-termsafety.Three lens types
basedonanatomical locationhavebeendeveloped—angle sup-
ported, iris fixated, andposterior chamber—eachwith its par-
ticular risk to benefit profile. Angle-supported implants can
induce endothelial cell loss and corneal decompensation, as
well as pupil ovalization, whereas iris-fixated implants pose
risksof cataract, cornealdecompensation,endothelial cell loss,
anddislocation.1 Posterior chamber PILs are intended tovault
over the crystalline lens, but anterior subcapsular cataractwas
soon recognized as a relatively common occurrencewith this
design, especially with longer follow-up.
On the basis of the assumption that cataract is a conse-
quence of intermittent lens touch and chronic low-grade in-
flammation, aswell as insufficientnutritionand impeded flow
between the implant and the crystalline lens, early posterior
chamber phakic lens designs were later modified to increase
the vault gap (ie, the space between the posterior PIL surface
and theanterior crystalline lens capsule).A retrospective com-
parative study2 of these designs appears to confirm that the
vault gap is inversely related to cataract risk.Now that this de-
sign iterationhasbeenavailable for anumberof years, it is im-
portant to reevaluate the cataract risk associated with poste-
rior chamber PILs for myopic and hyperopic corrections.
Igarashietal3 reportedthe8-year follow-upof theV4model
Visian implantable collamer lens (Staar Surgical AG) in 41 pa-
tients with myopia. Although refractive results were excel-
lent,with amean (SD) logMARuncorrecteddistance acuity of
0.02 (0.33) at 8 years after surgery and 73% of eyes with un-
corrected distance acuity of 20/20 or better, 17% of eyes that
lost at least 1 line of best-corrected acuity, and 7%of eyes that
lost2ormore lines,5%ofeyes requiredcataractextractiondur-
ing this 8-yearperiod.Ofnote, aprogressive reduction invault
gapwas observed at 1 and 6months and 1, 4, and 8 years after
surgery, with a significant difference in the 1-month, 4-year,
and 8-year estimates. In this cohort, intraocular pressurewas
monitored during the 8 years, but no increase was observed.
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